Health Economics›Transformed lymphoma›All lines of therapy

All lines of therapy

Transformed lymphoma · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~13.2 mo	—	~2	~R 573 911 PFS proxy · indirect	1
Glofitamab monotherapy Variant #01	—	R 193 746	21d	—	—	~11	~R 1 485 388 indirect	—
Lenalidomide and Rituximab (R2) Variant #08	—	R 134 502	28d	—	~8.5 mo	~11	~R 396 684 PFS proxy · indirect	1
OFAR Variant #01	—	R 65 637	28d	—	—	~6	~R 238 397 indirect	—
R-GDP Variant #01	—	R 30 037	21d	—	~31.1 mo	~6	~R 180 224 PFS proxy · indirect	1
R-DHAP Variant #01	—	R 29 945	21d	—	~31.1 mo	~3	~R 89 835 PFS proxy · indirect	2
R-EPOCH Variant #01	—	R 28 380	21d	—	—	~6	~R 170 281 indirect	—
Bendamustine monotherapy Variant #01	—	R 7 084	—	~16.5 mo	—	~8	~R 56 672 PFS proxy · indirect	2
Lenalidomide and Tafasitamab Variant #01 Partial	—	R 5 445	28d	—	—	~12	~R 65 340 indirect	—
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	~8.7 mo	—	~24	~R 52 272 PFS proxy · indirect	3
Loncastuximab tesirine monotherapy Variant #01 Partial	—	—	21d	—	—	~16	—	—
Axicabtagene ciloleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	1
131Iodine-Tositumomab monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Selinexor monotherapy Variant #01 Partial	—	—	7d	~2.8 mo	—	~2	—	1
Tisagenlecleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Epcoritamab monotherapy Variant #01 Partial	—	—	28d	—	—	~6	—	—

17 of 17 regimens shown